Is hypertriglyceridemia atherogenic?

Ross, 1999, Atherosclerosis  an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Bezin, 2017, Impact of a public media event on the use of statins in the French population, Arch Cardiovasc Dis, 110, 91, 10.1016/j.acvd.2016.05.002 Endo, 1992, The discovery and development of HMG-CoA reductase inhibitors, J Lipid Res, 33, 1569, 10.1016/S0022-2275(20)41379-3 Baigent, 2010, Cholesterol treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Catapano, 2016, 2016 ESC/EAS guidelines for the management of dyslipidaemias, Eur Heart J, 37, 2999, 10.1093/eurheartj/ehw272 Nordestgaard, 2016, Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology, Circ Res, 118, 547, 10.1161/CIRCRESAHA.115.306249 Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J, 32, 1345, 10.1093/eurheartj/ehr112 Reiner, 2011, ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Berglund, 2012, Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 97, 2969, 10.1210/jc.2011-3213 Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management, Lancet Diabetes Endocrinol, 2, 655, 10.1016/S2213-8587(13)70191-8 Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628 Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797 Landray, 2014, Niacin for reduction of cardiovascular risk, N Engl J Med, 371, 1943 Group, 2017, Effects of anacetrapib in patients with atherosclerotic vascular disease, N Engl J Med, 377, 1217, 10.1056/NEJMoa1706444 Tardif, 2016, Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes, Circ Cardiovasc Genet, 9, 340, 10.1161/CIRCGENETICS.116.001405 Tardif, 2015, Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib, Circ Cardiovasc Genet, 8, 372, 10.1161/CIRCGENETICS.114.000663 Zilversmit, 1979, Atherogenesis: a postprandial phenomenon, Circulation, 60, 473, 10.1161/01.CIR.60.3.473 Sarwar, 2007, Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies, Circulation, 115, 450, 10.1161/CIRCULATIONAHA.106.637793 Nordestgaard, 2007, Non fasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA, 298, 299, 10.1001/jama.298.3.299 Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease, J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026 Dron, 2017, Genetics of triglycerides and the risk of atherosclerosis, Curr Atheroscler Rep, 19, 31, 10.1007/s11883-017-0667-9 Jorgensen, 2014, Loss-of-function mutations in APOC3 and risk of ischemic vascular disease, N Engl J Med, 371, 32, 10.1056/NEJMoa1308027 Carlson, 1988, Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid, Acta Med Scand, 223, 405, 10.1111/j.0954-6820.1988.tb15891.x Khetarpal, 2016, Targeting ApoC-III to reduce coronary disease risk, Curr Atheroscler Rep, 18, 54, 10.1007/s11883-016-0609-y Gaudet, 2015, Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia, N Engl J Med, 373, 438, 10.1056/NEJMoa1400283 Nordestgaard, 2014, Triglycerides and cardiovascular disease, Lancet, 384, 626, 10.1016/S0140-6736(14)61177-6 Peng, 2017, Hypertriglyceridemia and atherosclerosis, Lipids Health Dis, 16, 233, 10.1186/s12944-017-0625-0